Not Yet RecruitingNot Applicable

Remimazolam TIVA-Flumazenil Antagonism in Short-duration ENT Surgeries

600 participantsStarted 2026-02-01

Plain-language summary

This study plans to categorize patients who underwent short-duration ENT surgeries with remimazolam TIVA combined with flumazenil antagonism based on whether their intraoperative BIS values were maintained below 60.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-65 years * ASA I-III * Underwent short-duration ENT surgery * Underwent remimazolam TIVA combined with flumazenil antagonism. * Continuous intraoperative BIS monitoring Exclusion Criteria: * Comorbid severe underlying diseases * Intraoperative BIS data were missing or incompletely recorded * Severe lack of medical records

What they're measuring

Incidence of intraoperative awareness

Timeframe: 2hours

Trial details

NCT IDNCT07389798

SponsorTongji Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-02-28

Contact for this trial

mujun chang, Dr

+862783663625 changmujun@hotmail.com

View on ClinicalTrials.gov More Remimazolam trials